According to reports, Cantor Fitzgerald CEO Howard Lutnick is now in the running to become President-Elect Trump's Treasury ...

Additionally, ROTH Capital resumed Buy rating on June 15, 2022, with a target price of $8. Cantor Fitzgerald analysts, in their report published on June 2, 2022, also initiated Overweight rating and ...

Howard Lutnick, the billionaire chairman and CEO of Wall Street firm Cantor Fitzgerald, is potentially a candidate to be ...

On Tuesday, SoundHound AI Inc (SOUN) stock saw a decline, ending the day at $7.56 which represents a decrease of $-0.21 or -2.70% from the prior close of $7.77. The stock opened at $7.69 and touched a ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Kudlow has been named as a potential pick for treasury secretary by Reuters and Politico, but his odds are currently hovering below one percent, according to Polymarket. Do you have a story we should ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Cantor Fitzgerald CEO and President-elect Trump’s transition co-chair, Howard Lutnick, is said to be "campaigning hard" ...

The tabs remained hidden until an analyst at Cantor Fitzgerald spotted them and published a note about the bone density data ...

Cantor Fitzgerald analyst Olivia Brayer found supplementary bone marrow density data for Amgen’s obesity candidate MariTide ...

Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...